Clinical trial
MDMA Therapy in Veterans With PTSD
Abstract
A Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with PTSD.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticleMDMA
Aesthetic mediation and lateral agency: Rethinking trauma and drug consumption in 'crisis ordinariness'.
ArticlePsilocybin
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
PreprintMDMA